We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q3 Potential of Clorox (CLX): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Clorox (CLX - Free Report) to post quarterly earnings of $1.57 per share in its upcoming report, which indicates a year-over-year decline of 8.2%. Revenues are expected to be $1.71 billion, down 5.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 2.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Clorox metrics that Wall Street analysts commonly model and monitor.
Analysts forecast 'Net Revenue- Health and Wellness' to reach $597.23 million. The estimate indicates a change of -1.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Revenue- Household' should arrive at $515.48 million. The estimate indicates a change of -2% from the prior-year quarter.
Analysts' assessment points toward 'Net Revenue- International' reaching $258.40 million. The estimate indicates a year-over-year change of -16.7%.
The combined assessment of analysts suggests that 'Net Revenue- Lifestyle' will likely reach $314.14 million. The estimate indicates a change of -0.3% from the prior-year quarter.
It is projected by analysts that the 'Organic Revenue Growth - International' will reach 6.0%. Compared to the current estimate, the company reported 48% in the same quarter of the previous year.
The consensus estimate for 'Income before income taxes- Health and Wellness' stands at $176.17 million. The estimate compares to the year-ago value of $154 million.
The collective assessment of analysts points to an estimated 'Income before income taxes- International' of $27.86 million. The estimate compares to the year-ago value of $38 million.
According to the collective judgment of analysts, 'Income before income taxes- Lifestyle' should come in at $68.36 million. Compared to the current estimate, the company reported $64 million in the same quarter of the previous year.
The consensus among analysts is that 'Income before income taxes- Household' will reach $73.02 million. Compared to the present estimate, the company reported $74 million in the same quarter last year.
Shares of Clorox have demonstrated returns of -3.6% over the past month compared to the Zacks S&P 500 composite's -0.7% change. With a Zacks Rank #3 (Hold), CLX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q3 Potential of Clorox (CLX): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts expect Clorox (CLX - Free Report) to post quarterly earnings of $1.57 per share in its upcoming report, which indicates a year-over-year decline of 8.2%. Revenues are expected to be $1.71 billion, down 5.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 2.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Clorox metrics that Wall Street analysts commonly model and monitor.
Analysts forecast 'Net Revenue- Health and Wellness' to reach $597.23 million. The estimate indicates a change of -1.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Revenue- Household' should arrive at $515.48 million. The estimate indicates a change of -2% from the prior-year quarter.
Analysts' assessment points toward 'Net Revenue- International' reaching $258.40 million. The estimate indicates a year-over-year change of -16.7%.
The combined assessment of analysts suggests that 'Net Revenue- Lifestyle' will likely reach $314.14 million. The estimate indicates a change of -0.3% from the prior-year quarter.
It is projected by analysts that the 'Organic Revenue Growth - International' will reach 6.0%. Compared to the current estimate, the company reported 48% in the same quarter of the previous year.
The consensus estimate for 'Income before income taxes- Health and Wellness' stands at $176.17 million. The estimate compares to the year-ago value of $154 million.
The collective assessment of analysts points to an estimated 'Income before income taxes- International' of $27.86 million. The estimate compares to the year-ago value of $38 million.
According to the collective judgment of analysts, 'Income before income taxes- Lifestyle' should come in at $68.36 million. Compared to the current estimate, the company reported $64 million in the same quarter of the previous year.
The consensus among analysts is that 'Income before income taxes- Household' will reach $73.02 million. Compared to the present estimate, the company reported $74 million in the same quarter last year.
View all Key Company Metrics for Clorox here>>>
Shares of Clorox have demonstrated returns of -3.6% over the past month compared to the Zacks S&P 500 composite's -0.7% change. With a Zacks Rank #3 (Hold), CLX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>